Two-day <i>versus</i> seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial.

"Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article"

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Y.B.D. is employed by Medis Laboratories. Medis Laboratories did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the article and did not provide financial support in the form of authors’ salaries. Medis Laboratories provided support in the form of study treatments (levofloxacin and placebo) and laboratory tests. The specific roles of these authors are detailed in the ‘author contributions’ section. The funder did not provide support in the form of salaries for authors and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the article."

"This was a prospective, randomized, double-blind controlled study including patients admitted to the emergency department (ED) with AECOPD. The study was carried out from February 2018 to January 2021. The study protocol has been prepared in accordance with the revised Helsinki Declaration for Biomedical Research Involving Human Subjects and Guidelines for Good Clinical Practice. The study was approved by ethics committees of all participating centers prior to implementation (Monastir and Sousse Universities), and all included patients provided their written informed consent. The study was registered at www.clinicaltrials.gov (NCT03698682)."